Novo Nordisk A/S said that a cardiovascular outcomes study for one of its newest products, Tresiba, is proceeding ahead of schedule, raising the prospect that data could be submitted to the Food and Drug Administration in the first half of 2015 with a new assessment thereafter. Tresiba was turned down by the FDA in 2013.
